Precipio, Inc.
PRPO
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $48.9M
$27.40
▲ +4.90%
P/E
-29.46
Mkt Cap
$48.9M
52-Wk Range
$16.00–$33.63
52-Week Range
$16.00 - $33.63
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 30.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Turning profitable
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+16.6% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying PRPO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 16, 2026
AUG 14, 2026
Reported EPS of -$0.12 vs -$2.00 consensus (+94.0% surprise). Revenue of $7.0M vs $1.7M expected (+319.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+94.0%
Revenue trend · last 2Q
—
+8%
Q1 26
Q2 26
$6.3M
$6.1M
Margins · last 2Q
Gross
51.3%
Operating
-9.8%
Profit
-3.6%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How PRPO stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.